Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 231

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Imatinib for refractory chronic graft-versus-host disease with fibrotic features

Olivieri, Attilio, Locatelli, Franco, Zecca, Marco, Sanna, Adele, Cimminiello, Michele, Raimondi, Roberto, Gini, Guido, Mordini, Nicola, Balduzzi, Adriana, Leoni, Pietro, Gabrielli, Armando, Bacigalupo, Andrea · 2009 · Blood

Abstract

We previously reported that patients with fibrotic, chronic graft-versus-host disease (cGVHD) have antibodies activating the platelet-derived growth factor receptor pathway. Because this pathway can be inhibited by imatinib, we performed a pilot study including 19 patients with refractory cGVHD, given imatinib at a starting dose of 100 mg per day. All patients had active cGVHD with measurable involvement of skin or other districts and had previously failed at least 2 treatment lines. Patient median age was 29 years (range, 10-62 years), and median duration of cGvHD was 37 months (range, 4-107 months). The organs involved were skin (n = 17), lung (n = 11), and bowel (n = 5); 15 patients had sicca syndrome. Imatinib-related, grade 3 to 4 toxicity included fluid retention, infections, and anemia. Imatinib was discontinued in 8 patients: in 3 because of toxicity and in 5 because of lack of response (n = 3) or relapse of malignancy (n = 2). Overall response rate at 6 months was 79%, with 7 complete remissions (CRs) and 8 partial remissions (PRs). With a median follow-up of 17 months, 16 patients are alive, 14 still in CR or PR. The 18-month probability of overall survival is 84%. This study suggests that imatinib is a promising treatment for patients with refractory fibrotic cGVHD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-02-204156

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 231

Metadata

Authors
Olivieri, A., Locatelli, F., Zecca, M., Sanna, A., Cimminiello, M., Raimondi, R., Gini, G., Mordini, N., Balduzzi, A., Leoni, P., Gabrielli, A., & Bacigalupo, A.
Venue
Blood
Published
2009-07-16
Volume
114
Issue
3
Pages
709-718
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2041548911
Cited by
231
References
3
FWCI
16.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imatinib for refractory chronic graft-versus-host disease with fibrotic features. https://app.cochat.ai/papers/10.1182/blood-2009-02-204156
The paper
Olivieri, A., Locatelli, F., Zecca, M., Sanna, A., Cimminiello, M., Raimondi, R., Gini, G., Mordini, N., Balduzzi, A., Leoni, P., Gabrielli, A., & Bacigalupo, A. (2009). Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. https://doi.org/10.1182/blood-2009-02-204156

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.